Methods to discriminate between nociceptive, neuropathic and nociplastic in children & adolescents: A systematic review of psychometric properties and feasibility.

The aim of this systematic review was to identify and critically analyse the tools available for categorising pain as nociceptive, neuropathic and nociplastic pain in children and adolescents. Studies were included if they (i) included children and adolescents with a mean age of 0-24 years old, (ii) examined assessment tools that categorise pain as nociceptive, neuropathic or nociplastic, and (iii) examined the psychometric properties of the tools. Sensitive searches were conducted in five online databases in March 2024. Eligible studies were assessed for risk of bias and quality by two authors using COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) criteria. The search yielded 26 studies for 11 tools. No assessment tool had evidence for all nine recommended psychometric properties. Quantitative Sensory Testing, a tool used to identify signs and symptoms of nociplastic and neuropathic pain, was the most studied tool and had moderate evidence for construct validity, criterion validity and reliability. Three self-reported questionnaires, the Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS), Central Sensitisation Inventory (CSI) and PainDETECT, had moderate evidence for construct validity and show promise as preliminary tools to identify possible neuropathic or nociplastic pain. However, they had low specificity when used in isolation. All assessment methods would benefit from further psychometric evaluation and validation in children and adolescents. PERSPECTIVE: This systematic review highlights the limited validation of pain assessment tools for children and adolescents. While Quantitative Sensory Testing and self-reported questionnaires show promise in identifying pain mechanisms, their applicability remains uncertain. Further psychometric validation is crucial to improve pain assessment and guide personalized treatment in young populations.